Search Results

You are looking at 201 - 210 of 524 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Nilofer Azad, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, J. Randolph Hecht, Sarah Hoffe, Joleen Hubbard, Steven Hunt, William Jeck, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Jennifer K. Maratt, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Eden Stotsky-Himelfarb, Anna Tavakkoli, Christopher G. Willett, Kristina Gregory, and Lisa Gurski

sphincter function are preferable but not possible in all cases. Preoperative chemoRT or TNT may result in tumor downsizing and a decrease in tumor bulk (see “Neoadjuvant and Adjuvant Therapy for Resectable Nonmetastatic Disease,” page 1148); sphincter

Full access

Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer

Bharathi Muthusamy, Pradnya D. Patil, and Nathan A. Pennell

likely minimal resistance created from the adjuvant therapy as the median duration of retreatment was 13 months, similar to the PFS with erlotinib in de novo metastatic disease. 24 , 25 The phase III ADJUVANT/CTONG1104 trial compared gefitinib with

Full access

Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach

Clair J. Beard, Shilpa Gupta, Robert J. Motzer, Elizabeth K. O'Donnell, Elizabeth R. Plimack, Kim A. Margolin, Charles J. Ryan, Joel Sheinfeld, and Darren R. Feldman

from low-risk patients and are not Table 1 Clinical Stage IA, NSGCT: Active Surveillance treated with adjuvant therapies. 16 , 32 Investigators at Princess Margaret Hospital followed 125 high-risk patients with the following protocol

Full access

Invasive Breast Cancer

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars

treatment should not be compromised when decisions regarding breast reconstruction are made. Systemic Adjuvant Therapy After surgical treatment, adjuvant systemic therapy should be considered. The published results of the Early Breast Cancer

Full access

Breast Cancer

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff

the daily management of breast cancer patients? Eur J Cancer 2000 ; 36 : 1755 – 1761 . 40 Thor AD Berry DA Budman DR . erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer . J Natl Cancer Inst 1998 ; 90

Full access

Geographic Variation of Adjuvant Breast Cancer Therapy Initiation in the United States: Lessons From Medicare Part D

John A. Charlson, Emily L. McGinley, Ann B. Nattinger, Joan M. Neuner, and Liliana E. Pezzin

initially demonstrated in the mid-1980s, 3 or an aromatase inhibitor (AI). Beginning in 2005, recommendations from ASCO suggested that adjuvant therapy for postmenopausal women with HR+ breast cancer include an AI, either alone or in sequence after

Full access

Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations

Cesar A. Santa-Maria, Maureen O’Donnell, Raquel Nunes, Jean L. Wright, and Vered Stearns

pCR, and the demonstrated toxicity in the adjuvant phase of treatment, clinicians may discuss potential benefits versus toxicity with individuals to determine whether to continue adjuvant pembrolizumab. What Adjuvant Therapies Should Be Given to

Full access

Evaluation of AJCC and an Alternative Tumor Classification System for Primary Vulvar Squamous Cell Carcinoma

Sarah T. Le, Pritesh S. Karia, Beverley J. Vollenhoven, Robert J. Besaw, Colleen M. Feltmate, and Chrysalyne D. Schmults

involvement (69%), and without perineural invasion (96%) or lymphovascular invasion (94%). Most tumors were primarily resected (81%), and most adjuvant therapy was used in higher T-class cases (see supplemental eTable 2) . Of patients undergoing excision, 15

Full access

A Routine Laboratory Data–Based Model for Predicting Recurrence After Curative Resection of Stage II Colorectal Cancer

Zhong Ye, Chun Wang, Limin Guo, Juan P. Palazzo, Zhixing Han, Yinzhi Lai, Jing Jiang, James A. Posey, Atrayee Basu Mallick, Bingshan Li, Li Jiang, and Hushan Yang

only a small portion of patients with stage II CRC, but is unnecessary in up to 70% of patients who might be cured by surgery alone. 5 , 6 According to a recent Cochrane systematic review, adjuvant therapy improves overall survival (OS) in <10% of

Full access

Sequential Versus Concurrent Chemoradiation Therapy by Surgical Margin Status in Resected Non–Small Cell Lung Cancer

Vivek Verma, Amy C. Moreno, Waqar Haque, Penny Fang, and Steven H. Lin

therapy referred to starting chemotherapy and RT within 14 days of each other, with the remainder designated as sequential. 25 , 26 Patients with an interval of >6 months from surgery to adjuvant therapy, or between adjuvant RT and chemotherapy, were